賽託生物(300583.SZ)2019年度淨利潤預降52%-63%
格隆匯1月23日丨賽託生物(300583.SZ)公佈,預計2019年度歸屬於上市公司股東的淨利潤4665.22萬元-6052.18萬元,同比下降52%-63%。
報告期內,公司按照經營計劃有序開展各項業務,在建項目得到有效推動,科研項目取得階段性成果,產業鏈得到進一步延伸。報告期內,受研發投入增加和市場波動等因素影響,預計2019年歸屬於上市公司股東的淨利潤較上年同期下降52%至63%之間,具體如下:
1、報告期內, 公司在研項目推進提速,繼續加大對新產品研發的投入, 全年研發支出預計4856萬元,較上年增加約913.9萬元。
2、公司繼續推進戰略調整和業務轉型,公司發展戰略重新定位於產業鏈內延伸,致力於將公司打造成為世界一流的集藥物中間體、高端原料藥、製劑為一體的覆蓋研發、生產、銷售全產業鏈生物技術企業。2019年是公司戰略轉型的關鍵年份,隨着公司業務的轉型升級,高端原料藥和製劑產品相關的人員配備、質量體系搭建等相關支出隨之增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.